Literature DB >> 19593559

Monitoring cancer therapy with PET: probably effective, but more research is needed.

Giovanni Lucignani1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19593559     DOI： 10.1007/s00259-009-1214-x

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  13 in total

Review 1.  Targeted imaging: an important biomarker for understanding disease progression in the era of personalized medicine.

Authors:  William C Eckelman; Richard C Reba; Gary J Kelloff
Journal:  Drug Discov Today       Date:  2008-07-24       Impact factor: 7.851

Review 2.  Considerations for the use of imaging tools for phase II treatment trials in oncology.

Authors:  Lalitha K Shankar; Annick Van den Abbeele; Jeff Yap; Robert Benjamin; Scott Scheutze; T J Fitzgerald
Journal:  Clin Cancer Res       Date:  2009-03-10       Impact factor: 12.531

Review 3.  Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development.

Authors:  Gary J Kelloff; John M Hoffman; Bruce Johnson; Howard I Scher; Barry A Siegel; Edward Y Cheng; Bruce D Cheson; Joyce O'shaughnessy; Kathryn Z Guyton; David A Mankoff; Lalitha Shankar; Steven M Larson; Caroline C Sigman; Richard L Schilsky; Daniel C Sullivan
Journal:  Clin Cancer Res       Date:  2005-04-15       Impact factor: 12.531

4.  The role of 18F-FDG PET/CT in evaluation of early response to neoadjuvant chemotherapy in patients with locally advanced breast cancer.

Authors:  Amandeep Kumar; Rakesh Kumar; Vathalaru Seenu; Sidharatha Datta Gupta; Madhavi Chawla; Arun Malhotra; Sada Nand Mehta
Journal:  Eur Radiol       Date:  2009-02-13       Impact factor: 5.315

5.  FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas.

Authors:  Matthias R Benz; Johannes Czernin; Martin S Allen-Auerbach; William D Tap; Sarah M Dry; David Elashoff; Kira Chow; Vladimir Evilevitch; Jeff J Eckardt; Michael E Phelps; Wolfgang A Weber; Fritz C Eilber
Journal:  Clin Cancer Res       Date:  2009-04-07       Impact factor: 12.531

6.  Validation of novel imaging methodologies for use as cancer clinical trial end-points.

Authors:  D J Sargent; L Rubinstein; L Schwartz; J E Dancey; C Gatsonis; L E Dodd; L K Shankar
Journal:  Eur J Cancer       Date:  2008-12-16       Impact factor: 9.162

7.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

Authors:  E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij
Journal:  Eur J Cancer       Date:  2009-01       Impact factor: 9.162

Review 8.  Monitoring response to therapeutic interventions in patients with cancer.

Authors:  Ken Herrmann; Bernd Joachim Krause; Ralph A Bundschuh; Tobias Dechow; Markus Schwaiger
Journal:  Semin Nucl Med       Date:  2009-05       Impact factor: 4.446

9.  Early prediction of response to first-line chemotherapy by sequential [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with advanced colorectal cancer.

Authors:  P Byström; A Berglund; U Garske; H Jacobsson; A Sundin; P Nygren; J-E Frödin; B Glimelius
Journal:  Ann Oncol       Date:  2009-01-22       Impact factor: 32.976

10.  Using fluorodeoxyglucose positron emission tomography to assess tumor volume during radiotherapy for non-small-cell lung cancer and its potential impact on adaptive dose escalation and normal tissue sparing.

Authors:  Mary Feng; Feng-Ming Kong; Milton Gross; Shaneli Fernando; James A Hayman; Randall K Ten Haken
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-03-15       Impact factor: 7.038
View more
  3 in total

Review 1.  Molecular imaging: current status and emerging strategies.

Authors:  M A Pysz; S S Gambhir; J K Willmann
Journal:  Clin Radiol       Date:  2010-07       Impact factor: 2.350

2.  Impact of rigid and nonrigid registration on the determination of 18F-FDG PET-based tumour volume and standardized uptake value in patients with lung cancer.

Authors:  Aleksandar Grgic; Elena Ballek; Jochen Fleckenstein; Norbert Moca; Stephanie Kremp; Andrea Schaefer; Jan-Martin Kuhnigk; Christian Rübe; Carl-Martin Kirsch; Dirk Hellwig
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-01-22       Impact factor: 9.236

3.  Metabolic response evaluated by 18F-FDG PET/CT as a potential screening tool in identifying a subgroup of patients with advanced non-small cell lung cancer for immediate maintenance therapy after first-line chemotherapy.

Authors:  Seung Hwan Moon; Su-Hee Cho; Lee Chun Park; Jun Ho Ji; Jong-Mu Sun; Jin Sock Ahn; Keunchil Park; Joon Young Choi; Myung-Ju Ahn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-04-18       Impact factor: 9.236
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.